At a glance
ClinicalIndex Comparison RecordN/ACompleted· 73 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NON-INTERVENTIONAL STUDY TO REVIEW THE CHANGES OF DEPRESSION AFTER FIRST-YEAR OF TOFACITINIB TREATMENT IN RHEUMATOID ARTHRITIS (XELJANZ (Registered))
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 73 participants across 6 sites.
Detailed Summary
12-month, single arm, prospective, non-interventional, multi-center study according to Czech legal definitions (Law 378/2007 Sb.).The primary objective of this study is to describe and evaluate the changes of depression level within 12 months from the start of tofacitinib therapy in patients with RA and at least minimal level of depression. Primary goal is to find out if treatment by tofacitinib reduces the depression by at least 10% during 12 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCzechia
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2020
Primary CompletionFeb 2024
TodayJul 2026
First PostedJun 20, 2019
Enrollment StartJul 23, 2020
Primary CompletionFeb 7, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.0 years ago